Baillie Gifford & Co’s Unity Biotechnology UBX Stock Holding History

Baillie Gifford & Co’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-58,911	Closed	-$233K	–	494
2022 Q3	$233K	Hold	58,911	–	–	﹤0.01%	291
2022 Q2	$332K	Hold	58,911	–	–	﹤0.01%	293
2022 Q1	$660K	Hold	58,911	–	–	﹤0.01%	282
2021 Q4	$860K	Hold	58,911	–	–	﹤0.01%	281
2021 Q3	$1.77M	Sell	58,911 -171,500	-74%	-$6.05M	﹤0.01%	266
2021 Q2	$10.7M	Sell	230,411 -149,890	-39%	-$7.22M	0.01%	244
2021 Q1	$22.8M	Hold	380,301	–	–	0.01%	220
2020 Q4	$19.9M	Hold	380,301	–	–	0.01%	202
2020 Q3	$13.2M	Hold	380,301	–	–	0.01%	198
2020 Q2	$33M	Hold	380,301	–	–	0.03%	148
2020 Q1	$22.1M	Hold	380,301	–	–	0.02%	144
2019 Q4	$27.4M	Hold	380,301	–	–	0.03%	147
2019 Q3	$23.2M	Hold	380,301	–	–	0.03%	148
2019 Q2	$36.1M	Hold	380,301	–	–	0.04%	140
2019 Q1	$30.8M	Hold	380,301	–	–	0.03%	142
2018 Q4	$61.8M	Hold	380,301	–	–	0.08%	108
2018 Q3	$62M	Hold	380,301	–	–	0.07%	113
2018 Q2	$57.3M	Buy	+380,301	New	+$55.6M	0.06%	107

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co's UBX Position: Q4 2022 in Review

Baillie Gifford & Co sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 58,911 shares — an estimated $233K sold.

Baillie Gifford & Co first reported a position in UBX in Q2 2018 and held it in 18 quarters. The position peaked at $62M in Q3 2018. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

Baillie Gifford & Co reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
Baillie Gifford & Co sold 58,911 Unity Biotechnology shares in Q4 2022, an estimated $233K.
Baillie Gifford & Co first reported a position in Unity Biotechnology in Q2 2018 and held it in 18 quarters.
Baillie Gifford & Co's Unity Biotechnology position peaked at $62M in Q3 2018.
54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.